News | February 09, 2009

SNM Workshop Underscores Imaging’s Value in Drug Development

February 9, 2009 - Presenters at the workshop stressed the need for the correct imaging biomarker available to accelerate the completion of clinical trials, as well as imaging standardization, consistent manufacturing practices and regulatory considerations, at The SNM Clinical Trials Network Community Workshop held on Feb. 8, 2009, in Clearwater, FL.
Speakers from the field of molecular imaging, regulatory agencies and pharmaceutical developers focused on the critical need to increase the use of imaging biomarkers in clinical trials and called for immediate action.

"The time to develop new imaging biomarkers is now," said Jeff Evelhoch, vice president of imaging at Merck. "We must come together as a community to make this happen, working together to facilitate the regulatory process."

Experts in oncology, cardiology, dementia and cell therapeutics discussed the important role that imaging biomarkers - indicators of a particular disease state or a particular state of an organism - can play in drug development studies. Other speakers addressed the challenges that researchers and imagers currently face in harmonizing imaging results between different locations in a multicenter trial.

“SNM’s Clinical Trials Network was conceived just for this reason: to create a standardized protocol across multiple sites in the U.S. and internationally in order to expedite the creation of new biomarkers for use in clinical trials,” said Michael Graham, M.D., Ph.D., president-elect of SNM and a chair of SNM’s Clinical Trials Network. “We are currently registering potential imaging sites, assessing their ability to participate in the Clinical Trials Network, and looking forward to announcing the first clinical trial in late 2009.”

“The role of medical imaging in clinical trials is rapidly increasing due to the ability to provide patient assessment and early drug trial results,” said Gustav K. von Schulthess, M.D., Ph.D., professor and director of nuclear medicine, University Hospital, Zurich, Switzerland, who was the keynote speaker at the workshop. “SNM’s Clinical Trials Network is expected to assist greatly by creating and enforcing standards among multiple trial sites, which, in the end, will benefit imagers, pharmaceutical manufacturers and patients.”

Pharmaceutical developer representative Diane Jorkasky, M.D., FACP, and former vice president of Global Clinical Research Operations at Pfizer, helped the audience understand the industry perspective on the use of medical scanning in drug development, how different therapeutic areas view the value of that scanning and how “go/no-go” decisions are used when employing such imaging.

"Only through partnerships comprising researchers, pharmaceutical developers and government will we be able to achieve novel approaches necessary to establishing successful clinical trials," she said. According to Dr. Jorkasky, one of the key attributes of a standardized trials protocol is that imagers and pharmaceutical developers will have insight earlier whether a drug under development shows potential for truly helping patients who can benefit from molecular imaging pharmaceuticals.

Wendy Sanhai, Ph.D., senior scientific advisor, Immediate Office of the Commissioner, U.S. Food and Drug Administration, closed the day's presentations by acknowledging the critical role of medical imaging agents in early diagnosis, as well as patient care and monitoring disease progression. "Medical imaging techniques can provide real-time feedback on drug effectiveness and separate those patients who respond from those who do not and thus allow successful clinical decisions for the most effective treatment," she said.

Dr. Sanhai described clinical studies that incorporate imaging and that are currently underway in collaboration with multiple stakeholders. Her presentation provided updates on studies being facilitated within the Biomarker Consortium--a public-private research partnership of the Foundation for the National Institutes of Health--as well as efforts underway at FDA to facilitate biomarker development.

For more information: www.snm.org/clinicaltrials

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...